Of note, unmodified or pegylated variants of human recombinant IFN-α2a or IFN-α2b have been approved by the US Food and Drug Administration (FDA) and other regulatory agencies worldwide for use in patients with various neoplasms, including chronic myelogenous leukemia (CML) [33]. The gene discussed is IFNA2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.